Traditional generics bigwigs Teva, Mylan, Sandoz, Amneal and Endo have lost out to a group of six competitors in terms of U.S. weekly prescriptions.

WuXi Biologics says its plant in Wuxi, China, has gotten the go-ahead from the FDA to make HIV drug Trogarzo for TaiMed Biologics.

Smoke from a fire set off by welding sparks reportedly killed 10 workers and injured a dozen rescuers at a pharmaceutical plant in China.

Nobel laureate wants bigger PD-1 revenue cut; Takeda scouts buyers for Latin America business; Chinese genomics investor is forced out of U.S. firm.

Even as Aurobindo grows its footprint in the U.S., the FDA continues to find problems in its manufacturing.

Daiichi inks $6.9 billion ADC deal with AZ, appoints new CEO; Keytruda nabs first-line lung cancer nod in China.

Novartis’ Cosentyx has beaten out rivals from Eli Lilly and J&J to land a psoriasis nod in China.

Astellas is looking to snap up share with Xospata before an AML rival hits the scene, and new survival data could help speed that process along.